Khémaies Slimane

Breast Cancer With Synchronous Metastases: Trends in Survival During a 14-Year Period

Fabrice André, Khémaies Slimane, Thomas Bachelot et al. · Journal of Clinical Oncology · 2004 · 396 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women With Clinically Aggressive Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer

Yen‐Shen Lu, Eznal Izwadi Bin Mohd Mahidin, Hamdy A. Azim et al. · Journal of Clinical Oncology · 2024 · 79 citations · Full text

Medicine, Oncology, Pharmacology +17

Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib

Maria Serova, Armand de Gramont, Annemilaï Tijeras‐Raballand et al. · Cancer Chemotherapy and Pharmacology · 2013 · 42 citations

Medicine, Oncology, Pharmacology +14

Abstract GS1-10: Primary results from the randomized Phase II RIGHT Choice trial of premenopausal patients with aggressive HR+/HER2− advanced breast cancer treated with ribociclib + endocrine therapy vs physician’s choice combination chemotherapy

Yen‐Shen Lu, Eznal Izwadi Bin Mohd Mahidin, Hamdy A. Azim et al. · Cancer Research · 2023 · 41 citations

Medicine, Oncology, Pharmacology +16

Mitotic Index and Benefit of Adjuvant Anthracycline-Based Chemotherapy in Patients With Early Breast Cancer

Fabrice André, Ahmed Khalil, Khémaies Slimane et al. · Journal of Clinical Oncology · 2005 · 32 citations · Full text

Medicine, Oncology, Breast Oncology +12